tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

BLTE Stock Latest News

Promising Clinical Trials and Strong Financial Position Reinforce Buy Rating for Belite Bio
RatingsPromising Clinical Trials and Strong Financial Position Reinforce Buy Rating for Belite Bio
14d ago
BLTE
Belite Bio’s Tinlarebant: A Promising Investment with Breakthrough Potential for Stargardt Disease
PremiumRatings
Belite Bio’s Tinlarebant: A Promising Investment with Breakthrough Potential for Stargardt Disease
16d ago
BLTE
Belite Bio’s Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
Belite Bio’s Earnings Call: Progress Amid Challenges
17d ago
BLTE
Promising Clinical Trials and Regulatory Advancements Support Buy Rating for Belite Bio, Inc.
PremiumRatings
Promising Clinical Trials and Regulatory Advancements Support Buy Rating for Belite Bio, Inc.
17d ago
BLTE
Belite Bio Advances Retinal Disease Treatments Amid Financial Growth
PremiumCompany Announcements
Belite Bio Advances Retinal Disease Treatments Amid Financial Growth
18d ago
BLTE
Belite Bio Announces Q2 2025 Financial Results and Key Clinical Milestones
PremiumCompany AnnouncementsBelite Bio Announces Q2 2025 Financial Results and Key Clinical Milestones
18d ago
6K
BLTE
Belite Bio reports Q2 EPS (50c), consensus (42c)
Premium
The Fly
Belite Bio reports Q2 EPS (50c), consensus (42c)
18d ago
BLTE
Belite Bio, Inc. ADR (BLTE) Q2 Earnings Cheat Sheet
Premium
Pre-Earnings
Belite Bio, Inc. ADR (BLTE) Q2 Earnings Cheat Sheet
21d ago
BLTE
Belite Bio Announces $15 Million Direct Offering
PremiumCompany Announcements
Belite Bio Announces $15 Million Direct Offering
22d ago
6K
BLTE
Belite Bio prices 230,770 ADSs at $65.00 in registered direct offering
PremiumThe Fly
Belite Bio prices 230,770 ADSs at $65.00 in registered direct offering
22d ago
BLTE
Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential
PremiumRatings
Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential
2M ago
BLTE
Positive Buy Rating for Belite Bio Driven by Phase 3 PHOENIX Trial Milestone and Regulatory Designations
PremiumRatings
Positive Buy Rating for Belite Bio Driven by Phase 3 PHOENIX Trial Milestone and Regulatory Designations
2M ago
BLTE
Belite Bio Completes Enrollment for Phase 3 PHOENIX Trial on Tinlarebant
PremiumCompany AnnouncementsBelite Bio Completes Enrollment for Phase 3 PHOENIX Trial on Tinlarebant
2M ago
6K
BLTE
Belite Bio completes enrollment in PHOENIX trial
Premium
The Fly
Belite Bio completes enrollment in PHOENIX trial
2M ago
BLTE
Belite Bio management to meet with Maxim
Premium
The Fly
Belite Bio management to meet with Maxim
3M ago
BLTE
Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating
PremiumRatings
Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating
3M ago
BLTE
Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress
PremiumRatings
Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress
3M ago
BLTE
Belite Bio’s Tinlarebant Receives FDA Breakthrough Therapy Designation for Stargardt Disease
PremiumCompany Announcements
Belite Bio’s Tinlarebant Receives FDA Breakthrough Therapy Designation for Stargardt Disease
3M ago
6K
BLTE
Belite Bio announces Breakthrough Therapy Designation for Tinlarebant from FDA
PremiumThe Fly
Belite Bio announces Breakthrough Therapy Designation for Tinlarebant from FDA
3M ago
BLTE
Belite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength
PremiumCompany AnnouncementsBelite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength
4M ago
BLTE
Promising Clinical Trials and Strategic Developments Justify Buy Rating for Belite Bio
Premium
Ratings
Promising Clinical Trials and Strategic Developments Justify Buy Rating for Belite Bio
4M ago
BLTE
Belite Bio Advances Clinical Trials Amid Financial Challenges
Premium
Company Announcements
Belite Bio Advances Clinical Trials Amid Financial Challenges
4M ago
BLTE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >